•  
  •  
 

Rehabilitation Practice and Science

Translated Title

探究影響膀胱功能的藥物與脊髓損傷病患罹患膀胱腫瘤的風險

Abstract

Bladder cancer (BC) is a chronic complication of spinal cord injury (SCI). Limited studies have focused on the risks of BC in SCI patients using voiding function medication for bladder dysfunction. In this retrospective, national-wide, population-based cohort study, SCI patients with registration in the National Health Insurance Research Database (NHIRD) from 1998 to 2013 were included. We investigated the risk of BC in SCI patients administered voiding function medications and other comorbidities by 2-year landmark analysis. SCI patients were divided into medication user (bethanechol, oxybutynin, or tolterodine) and non-medication user groups at landmark period. They were followed until the development of BC, death, or any other reason for loss to follow-up. Cox regression models and competing risk regression were used to investigate BC risks. In our study, 47,373 SCI patients registered in our database met the inclusion criteria. After exclusion, 22,974 patients were divided into medication user and non-medication user groups. There were no increased BC risks in medication user group, comparing to non-medication user group, neither in different cDDD nor subgroup analyses. In the subgroup analysis of medication user group, age more than 45 years (aHR: 1.93-2.45), male (aHR: 1.62), higher economic levels (aHR: 1.82), renal stone (aHR: 2.43), and chronic urinary tract infection (aHR: 2.18) were independent factors increased BC. Voiding dysfunction medication did not increase the risk of BC in SCI. Physician should still pay attend on other risk factors of BC in SCI patients.

Language

English

First Page

91

Last Page

104

Download

Share

COinS